Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca plc : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings better than estimates. In recent months, the 15 analysts from Thomson Reuters consensus have not revised their EPS estimates.

Annual earnings per share is expected at 1.93 USD for 2018 (- 18.4% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread
23 641
24 336
-2,9%
23 002
22 638
1,6%
22 465
21 834
2,9%

22 048

23 417
Operating income (EBITDA)
Million $
Released
Forecast
Spread
8 150
8 352
-2,4%
9 078
7 574
20%
9 891
8 207
21%

7 439

7 928
Operating profit (EBIT)
Million $
Released
Forecast
Spread
6 902
6 660
3,6%
6 721
6 455
4,1%
6 855
5 815
18%

5 819

6 276
Pre-Tax Profit (EBT)
Million $
Released
Forecast
Spread
3 069
3 146
-2,4%
3 406
2 344
45%
2 227
3 047
-27%

3 030

3 421
Net income
Million $
Released
Forecast
Spread
2 825
2 732
3,4%
3 499
2 519
39%
3 001
2 251
33%

2 495

2 793
EPS
 $
Released
Forecast
Spread
2,23
2,17
2,8%
2,77
2,18
27%
2,37
2,00
19%

1,93

2,16
Announcement Date02/04/201602/02/201702/02/2018

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
04/18LONDON STOCK EXCHANGE : FTSE 100 dips on sluggish euro zone PMI, Unilever sparkl..
RE
04/17London's shares off six-month highs, Bunzl suffers worst day in a decade
RE
04/15LONDON STOCK EXCHANGE : London's FTSE 100 subdued, IWG lifts midcaps
RE
04/15LONDON STOCK EXCHANGE : London's FTSE 100 tugged down by miners; IWG lifts midca..
RE
04/10ASTRAZENECA : Lynparza approved in EU for the treatment of germline BRCA-mutated..
PU
04/10ASTRAZENECA : Lynparza Approved in EU to Treat a Form of Breast Cancer
DJ
04/10ASTRAZENECA : Lynparza approved in EU for the treatment of germline BRCA-mutated..
AQ
04/04ASTRAZENECA : Positive results from Fasenra Phase II trial in hypereosinophilic ..
PU
04/02LONDON STOCK EXCHANGE : FTSE 100 at six-month high as Brexit-wounded pound lifts..
RE
04/01Correction to Astra, Hutchison China Cancer Drug Article on Sunday
DJ
More news
Financials ($)
Sales 2019 23 518 M
EBIT 2019 6 121 M
Net income 2019 3 070 M
Debt 2019 11 994 M
Yield 2019 3,70%
P/E ratio 2019 35,17
P/E ratio 2020 25,65
EV / Sales 2019 4,74x
EV / Sales 2020 4,30x
Capitalization 99 491 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,6 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-0.99%99 491
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 445
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055